← Leaderboards
Pablo Elias Vivas-Mejia
University Of Puerto Rico Rio Piedras
$2,906,673
Attributed
$2,906,673
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $351.7K · FY2012–25$500K$375K$250K$125K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,906,673 · 4
By mechanism
U54$1,712,187 · 1
R16$605,902 · 1
K22$525,461 · 1
P20$63,123 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorThe Cancer Genome AtlasPathway InteractionsResistanceMessenger RnaRna InterferenceMalignant NeoplasmsOverexpressionMolecularProteinsMediatingCancer CellCisplatinGenesLiposomesCellsCell ProliferationChemotherapyCancer PatientBiologicalCell SurvivalCessation Of LifeMalignant Neoplasm Of OvaryTumor Growth
Grant awards (13)
Unraveling the Role of MMP3 in the Cisplatin Resistance of Ovarian Cancer$153,030
R16 · FY2025 · GM · contact PI
Unraveling the Role of MMP3 in the Cisplatin Resistance of Ovarian Cancer$152,872
R16 · FY2024 · GM · contact PI
Unraveling the Role of MMP3 in the Cisplatin Resistance of Ovarian Cancer$150,000
R16 · FY2023 · GM · contact PI
Unraveling the Role of MMP3 in the Cisplatin Resistance of Ovarian Cancer$150,000
R16 · FY2022 · GM · contact PI
Upstream Regulation and Downstream effectors of c-MYC in Ovarian Cancer$331,034
U54 · FY2021 · MD · contact PI
Upstream Regulation and Downstream effectors of c-MYC in Ovarian Cancer$348,563
U54 · FY2020 · MD · contact PI
Upstream Regulation and Downstream effectors of c-MYC in Ovarian Cancer$351,728
U54 · FY2019 · MD · contact PI
Upstream Regulation and Downstream effectors of c-MYC in Ovarian Cancer$340,378
U54 · FY2018 · MD · contact PI
Upstream Regulation and Downstream effectors of c-MYC in Ovarian Cancer$340,484
U54 · FY2017 · MD · contact PI
Targeting c-MYC Overcomes Temsirolimus and Cisplatin Resistance of Ovarian Cancer$171,827
K22 · FY2014 · CA · contact PI
Targeting c-MYC Overcomes Temsirolimus and Cisplatin Resistance of Ovarian Cancer$172,265
K22 · FY2013 · CA · contact PI
Targeting c-MYC Overcomes Temsirolimus and Cisplatin Resistance of Ovarian Cancer$181,369
K22 · FY2012 · CA · contact PI
GENE EXPRESSION PROFILE IN HOMOGENOUS CELL POPULATION$63,123
P20 · FY2004 · RR